| 摘要 |
<p>Pyrimidine derivatives of formula (I) wherein: Qh<SUB>1 </SUB>and Q<SUB>2 </SUB>are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Q<SUB>1 </SUB>and Q<SUB>2 </SUB>or both Q<SUB>1 </SUB>and Q<SUB>2 </SUB>is substituted on a ring carbon by one group selected from sulphamoyl, N-(C<SUB>1-4</SUB>alkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(C<SUB>1-4</SUB>alkyl)sulphamoyl (optionally substituted by halo or hydroxy), C<SUB>1-4</SUB>alkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia'): wherein Q<SUB>1</SUB>, Q<SUB>2</SUB>, G, R<SUP>1</SUP>, Y, Z, Q<SUB>3</SUB>, n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described</p> |
